NEW YORK – Gilead Sciences and Second Genome have launched a collaboration to identify biomarkers linked to clinical response in up to five of Gilead's pipeline compounds in inflammation, fibrosis, and other diseases. The team aims to also identify potential targets and drug candidates for treating inflammatory bowel disease (IBD).
As part of the project, South San Francisco-based Second Genome will use its Microbiome Analytics Platform to identify novel biomarkers associated with clinical responses to Gilead's investigational medicines.